1. As of noon trading, Gilead ( GILD) is up $7.88 (12.1%) to $72.90 on heavy volume Thus far, 13.9 million shares of Gilead exchanged hands as compared to its average daily volume of 7.0 million shares. The stock has ranged in price between $71.74-$73.25 after having opened the day at $72.31 as compared to the previous trading day's close of $65.01. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $49.1 billion and is part of the drugs industry. The company has a P/E ratio of 20.1, above the S&P 500 P/E ratio of 17.7. Shares are up 58.4% year to date as of the close of trading on Friday. Currently there are 20 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Gilead Ratings Report now. If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD). A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.